A PHASE II RANDOMIZED STUDY OF NovoTTF THERAPY VERSUS SUPPORTIVE CARE IN NON-SMALL CELL LUNG CANCER PATIENTS WITH 1-5 BRAIN METASTASES FOLLOWING OPTIMAL STANDARD LOCAL TREATMENT

被引：0
|
作者：
Weinberg, Uri [1 ]
Kirson, Eilon [2 ]
Farber, Ori [2 ]
Palti, Yoram [1 ]
机构：
[1] Novocure GmbH, Luzern, Switzerland
[2] Novocure Ltd, Haifa, Israel
来源：
NEURO-ONCOLOGY | 2014年 / 16卷
关键词：
D O I：
10.1093/neuonc/nou265.35
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
NT-37
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Incidence and therapy of brain metastases in patients with locally advanced non-small cell lung cancer
    Zemanova, M
    Zatloukal, P
    Petruzelka, L
    Havel, L
    LUNG CANCER: CURRENT TOPICS, 2001, : 285 - 290
  • [32] The incidence and predictors of new brain metastases in patients with non-small cell lung cancer following discontinuation of systemic therapy
    London, Dennis
    Patel, Dev N.
    Donahue, Bernadine
    Navarro, Ralph E.
    Gurewitz, Jason
    Silverman, Joshua S.
    Sulman, Erik
    Bernstein, Kenneth
    Palermo, Amy
    Golfinos, John G.
    Sabari, Joshua K.
    Shum, Elaine
    Velcheti, Vamsidhar
    Chachoua, Abraham
    Kondziolka, Douglas
    JOURNAL OF NEUROSURGERY, 2022, 137 (02) : 544 - 554
  • [33] Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases
    Xu, Jianping
    Liu, Xiaoyan
    Yang, Sheng
    Shi, Yuankai
    ONCOLOGY RESEARCH, 2020, 28 (02) : 127 - 133
  • [34] Targeted Iressa therapy in patients with brain metastases from non-small cell lung cancer
    Si-Yu, W
    Wei, O
    Yong-Bin, L
    LUNG CANCER, 2005, 49 : S393 - S393
  • [35] DRUG THERAPY FOR PATIENTS WITH BRAIN METASTASES FROM NON-SMALL CELL LUNG CANCER.
    Naskhletashvili, David R.
    Gorbounova, Vera A.
    Bychkov, Mark B.
    Moskvina, Ekaterina A.
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S1173 - S1174
  • [36] Osimertinib plus local treatment for brain metastases versus osimertinib alone in patients with EGFR-Mutant Non-Small Cell Lung Cancer
    Tozuka, Takehiro
    Noro, Rintaro
    Mizutani, Hideaki
    Kurimoto, Futoshi
    Hakozaki, Taiki
    Hisakane, Kakeru
    Naito, Tomoyuki
    Takahashi, Satoshi
    Taniuchi, Namiko
    Yajima, Chika
    Hosomi, Yukio
    Hirose, Takashi
    Minegishi, Yuji
    Okano, Tetsuya
    Kamio, Koichiro
    Yamaguchi, Tomoyoshi
    Seike, Masahiro
    LUNG CANCER, 2024, 191
  • [37] Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer
    Ranson, M
    Davidson, N
    Nicolson, M
    Falk, S
    Carmichael, J
    Lopez, P
    Anderson, H
    Gustafson, N
    Jeynes, A
    Gallant, G
    Washington, T
    Thatcher, N
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (13): : 1074 - 1080
  • [38] A Randomized Phase II Trial of Gemcitabine plus Carboplatin: Biweekly versus Standard Schedules in Patients with Advanced Non-Small Cell Lung Cancer
    Hasegawa, Yukihiro
    Miura, Dai
    Kitamura, Chiho
    Suzuki, Takaya
    Kobayashi, Kazurna
    Sato, Nobuyuki
    CHEMOTHERAPY, 2013, 59 (05) : 346 - 353
  • [39] A phase II study of paclitaxel in patients with non-small cell lung cancer
    Voravud, N
    Sriuranpong, V
    Foofung, S
    EUROPEAN JOURNAL OF CANCER, 1995, 31A : 1111 - 1111
  • [40] Phase II study: WBRT ±temozolomide (TMZ) in patients with multiple brain metastases from non-small cell lung cancer (NSCLC)
    Marosi, C.
    Elandt, K.
    Preusser, M.
    Dieckmann, K.
    Nevinny, M.
    Knocke-Abulesz, T.
    Pfeifer, W.
    Stockhammer, G.
    Hammer, J.
    Zielinski, C. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345